Rhinoswab

European Launch of Revolutionary New Swab for Testing Children for Respiratory Diseases

The world’s most child-friendly respiratory swab was launched in Europe today at Medica 2022 in Dusseldorf, Germany.  Rhinoswab Junior is the first nasal swab developed specifically for children. Its unique design addresses one of the pandemics’ major challenges − testing reluctance − created by the fear, anxiety and discomfort associated with traditional combined throat and nose swabs. Rhinoswab Junior is … Read more

New study says there is a better swab for testing children for covid and other viruses

A new study suggests the traditional swab suffers from strong reluctance for use for children and a new Melbourne-designed Rhinoswab Junior is the preferred method of sample collection. The reluctance to test children for COVID-19 is due to the fear, anxiety and discomfort associated with the traditional combined throat and nose swabs. The “Less invasive … Read more

Study confirms new nasal swab is most accurate, comfortable and easy for kids

Rhinomed is pleased to advise of the forthcoming publication of a further study and data by researchers from the Murdoch Children’s Research Institute and the Royal Children’s Hospital (RCH) Melbourne confirming the efficacy and comfort of the world’s first nasal swab designed specifically for children – the Rhinoswab Junior. The study “Less invasive SARS-CoV-2 testing for children: … Read more

Surescreen Australia & Rhinomed – Rhinoswab Supply Deal

Rhinomed Limited is pleased to report that it has finalised an exclusive supply agreement with SureScreen Australia to supply Rhinoswabs and Rhinoswab Juniors for inclusion in SureScreen’s class-leading range of lateral flow point of care test kits in the Australian, New Zealand, Singapore and South Pacific markets. The first product to market will be the … Read more

Victorian Government orders Rhinoswab

Rhinomed has received an initial purchase order for one million Rhinoswabs from the Victorian Department of Health (DH) to support Victoria’s testing capability. This follows the recent NSW Health Pathology order of one million Rhinoswabs as announced on 11 August. Rhinomed’s Rhinoswab technology improves the sample collection process. As previously disclosed the Rhinoswab is substantially … Read more

First Government Orders for Rhinoswab

Rhinomed has received purchase orders and begun supplying NSW Health Pathology with an initial one million Rhinoswabs as part of their program to support testing capability. The company has commenced deliveries with these initial orders being fulfilled over coming weeks. Rhinomed is now scaling up its manufacturing facilities to respond to growing domestic and international … Read more

Rhinoswab Secures European CE Mark

Rhinomed is pleased to announce it has been advised by Medical Device Safety Service GmbH (MDSS) that an Authorized Representative’s Mandate according to the EU Regulation 2017/745 (MDR) is in place. As a result, Rhinomed has been issued a CE Certificate No.: 431330 for the new Rhinoswab. The successful registration and conformity with the relevant … Read more

Key Studies Confirm Rhinoswab’s Superior Performance

Rhinomed is pleased to report an important update on its Rhinoswab™ clinical program. In December 2020 the company established that the Rhinoswab was comparable to existing standard of care nasal swabs in detecting the SARS-CoV-2 virus in RT-PCR testing. This study was undertaken at the VIDRL (Peter Doherty Institute). Since December the company has further … Read more

Rhinoswab Detects SARS-CoV-2 in Doherty Institute rt-PCR STudy

Rhinomed is pleased to report positive data from its lab-based spiking study of Rhinomed’s new Rhinoswab conducted at the Victorian Infectious Diseases Reference Laboratory (VIDRL), part of The Peter Doherty Institute for Infection and Immunity (The Doherty) in Melbourne. The study’s objective was to demonstrate efficacy in detecting the SARS-CoV-2 virus at both low and … Read more

Rhinomed’s New High Comfort Nasal Swab Successfully Registered With Australian TGA

Rhinomed has successfully registered its easy to use, high load capturing, comfortable nasal swab with the Australian Therapeutic Goods Administration (TGA) as a Class 1 device. The new swab can comfortably collect samples from both nostrils simultaneously to test for the presence of upper respiratory tract diseases including influenza and coronavirus including SARS-CoV-2. The unique … Read more

Nasal swab Registered With US FDA

Rhinomed Limited is pleased to announce that it has successfully registered its novel nasal swab with the US FDA as a Class 1 device to collect samples from the nose to detect upper respiratory tract diseases including influenza and coronavirus strains. The successful registration and conformity with the relevant standards means that Rhinomed’s novel nasal … Read more

Rhinomed Developing New Nasal Swab

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in nasal airway and respiratory technology, is advanced in developing a new high-yielding nasal swab that can collect samples from the nose to test for the presence of upper respiratory tract diseases, including influenza and coronavirus strains. Read a full copy of the report here.